Wang, J., Xu, B., Ouyang, Q., Wang, Z., Zhang, Q., Ren, Y., Zhong, J., Sun, T., Tong, Z., Zhou, W., Wang, X., Zhong, Y., Zeng, X., Teng, Y., Sun, J., Xia, Y., Geng, C., Qiu, F., Zhao, H., Liao, N. (2025). ETER901: A randomized, open-label, phase III trial of anlotinib in combination with anti-PD-L1 antibody benmelstobart (TQB2450) versus nab-paclitaxel in first-line treatment of recurrent or metastatic triple-negative breast cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.1104